Skip to main content

Advertisement

Fig. 3 | BMC Gastroenterology

Fig. 3

From: Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial

Fig. 3

Flowchart of the study (as of February 1, 2016). *Treatment arm is assigned in double-blinded fashion; exact numbers of randomized patients per treatment arm are not known. APC, adenomatous polyposis coli; CPP-1X, eflornithine; EOT, end of treatment; PBO, placebo

Back to article page